Rosetta shares sell on a tough day for Wall Street

Rosetta Genomics picked a tough day to go public. Offering its shares on a day that saw the worst one-day drop in prices since 2001, the Israeli company garnered $26.3 million after selling shares at $7 each, 50 cents a share less than its lowest price range. Rosetta uses a computer algorithm to research microRNA gene sequences.

- read the report on Rosetta's IPO from Globes

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.